How to use Sogroya® for children

The Sogroya® pen is easy to learn to usea and designed with your lifestyle in mind.

Sogroya® 15 mg pen

aIn a study, 94 people used the Norditropin® FlexPro® (somatropin) injection 30 mg pen to inject into a foam cushion and rated it a 6.7 out of 7 (on a scale of 1 to 7, where 1 means “strongly disagree” and 7 means “strongly agree”), as “easy to learn to use.” The Norditropin® FlexPro® is similar to the Sogroya® pen.

Child riding a scooter
Children with the aim icon

Important things to know when starting or switching to Sogroya®

Your doctor will specify what dose is right for your child.

Check mark icon

If you are switching from a daily GH treatment, make sure at least 8 hours have passed between the last dose of your daily GH treatment and the first dose of Sogroya®.

Check mark icon

If you are switching from a weekly GH treatment, you can continue a once-weekly dosing schedule with Sogroya®.

Check mark icon

If you are new to GH treatment, start with the Sogroya® dosage strength indicated by your doctor.

Sogroya® is available in 3 different dosing strengths

Your child’s healthcare provider will tell you which Sogroya® pen is right for your child and how to dose it.

5 mg/1.5 mL
Sogroya® 5 mg pen
10 mg/1.5 mL
Sogroya® 10 mg pen
15 mg/1.5 mL
Sogroya® 15 mg pen

Learn to use the pen

New to the Sogroya® pen or looking for a refresher? Our step-by-step tutorial takes you through the process.

See the steps
Sogroya® pen injection steps

Injection instructions

This video may help you and your child learn more about the injection process.

Sogroya® pen injection instructions video thumbnail

How to use Sogroya®

The injection process includes 5 steps, from preparing the pen to storing or throwing it away when you’re done with it.b

Please see Instructions for Use for complete instructions.

bDo not share your Sogroya® pen and needles with another person. You may give another person an infection or get an infection from them. Do not use your Sogroya® pen without training from your healthcare provider. Make sure that you are confident in giving an injection with the Sogroya® pen before you start your treatment. If you are blind or have poor eyesight and cannot read the dose counter on the Sogroya® pen, do not use this Sogroya® pen without help. Get help from a person with good eyesight who is trained to use the Sogroya® pen.

Actor portrayal

Boy carrying a backpack
Preparing a Sogroya® pen

Pen shown is 10 mg/1.5 mL pen. Please see Instructions for Use for complete instructions for each dosage strength.

1. Prepare your Sogroya® pen

  • Wash your hands with soap and water. Then check the name, strength, and colored label on your pen to make sure that it contains Sogroya® in the right strength.
  • Pull off the pen cap. Turn the pen upside down 1 or 2 times to check that the Sogroya® in your pen is clear to almost clear and colorless to slightly yellow.
    If Sogroya® looks cloudy or you see visible particles, do not use the pen.
  • Get a new disposable needle and remove the paper tab.c Push the needle straight onto the pen and turn the needle clockwise until it is on tight.
    Always use a new needle for each injection. This reduces the risk of contamination, infection, leakage of Sogroya®, and blocked needles leading to incorrect dosing.
  • Pull off the outer needle cap and throw it away. Pull off the inner needle cap and throw it away too.

cNeedles are sold separately and may require a prescription.

Checking the flow of a Sogroya® pen

Pen shown is 10 mg/1.5 mL pen. Please see Instructions for Use for complete instructions for each dosage strength.

2. Check the flow with each new pen

  • Before using a new pen, check the flow to make sure Sogroya® can flow through the pen and needle.
  • Turn the dose selector clockwise one tick mark to select the smallest amount of medicine for the pen.
  • Hold the pen with the needle pointing up. Press and hold in the dose button until the dose counter returns to “0.” The “0” must line up with the dose pointer.
  • Check that a drop of Sogroya® appears at the needle tip. If no Sogroya® appears, repeat up to 6 times. If you still don’t see a drop of Sogroya®, replace the needle once and try again.
    Do not use your pen if a drop of Sogroya® does not appear after changing the needle. Call 1-888-NOVO-444 (1-888-668-6444) for help.
Checking the flow of a Sogroya® pen

Pen shown is 10 mg/1.5 mL pen. Please see Instructions for Use for complete instructions for each dosage strength.

3. Select your dose

  • Check that the dose counter is set to “0.”
  • Turn the dose selector clockwise to select the dose you need. Always use the dose pointer to select the exact dose. Do not rely on pen clicks.
  • If you select the wrong dose, you can turn the dose selector clockwise or counterclockwise to reach the correct dose.
  • If there is not enough Sogroya® left in the pen to select your full dose, you can either dispose of it (see step 5) and start over with a new pen or split your dose between your current pen and a new pen. To split your dose, inject the amount left in your current pen. Calculate how much Sogroya® you need to complete your dose, then perform steps 1 through 3 to prepare a new pen and select that amount.
    Only split your dose if you have been trained or advised by your healthcare provider on how to do this.
Injecting the Sogroya® pen

Pen shown is 10 mg/1.5 mL pen. Please see Instructions for Use for complete instructions for each dosage strength.

4. Inject your dose

  • Sogroya® can be injected under the skin in the upper arms, thigh,
    abdomen, or buttocks as instructed by your healthcare provider.
    Change the injection site every week.
  • Wipe the injection site with an alcohol swab and let the area dry.
  • Insert the needle into your skin as your healthcare provider has shown you.
    Make sure you can see the dose counter. Do not cover it with your fingers, as it could block the injection.
  • Press and hold down the dose button until the dose counter shows “0.” You may hear or feel a “click.”
  • Keep holding down the button with the needle in your skin and slowly count to 6.
  • Carefully remove the needle from your skin. You may see a drop of Sogroya® at the needle after injecting. This is normal and does not affect your dose.

Needle with the cap on

Pen shown is 10 mg/1.5 mL pen. Please see Instructions for Use for complete instructions for each dosage strength.

5. After your injection

  • Carefully remove the needle from the pen by turning the needle counterclockwise. Immediately place it in an appropriate sharps disposal container.
    Always throw away the needle after each injection.
  • Put the pen cap on your pen after each use to protect Sogroya® from direct light.
  • If you won’t reuse the pen, dispose of it in an appropriate sharps disposal container.
    Do not throw away loose needles and pens in your household trash.
Girl playing basketball in front of Sogroya® pens

The Sogroya® pen was designed with you in mind

Droplet with checkmark icon

Ready to use
Prefilled—no cartridges and no preparation of the medicine is required.

Temperature with check mark icon

Portable
Stable at room temperature (up to 77 ºF) for up to 3 days (72 hours).d

10 years

Familiar
Based on the FlexPro® with more than 10 years of patient experience.

dThe pen should be refrigerated (36 °F-46 °F). The pen can be taken in and out of a refrigerator as needed. The pen must be discarded 6 weeks after first use, or if it has been frozen, or in temperatures warmer than 86 °F. Keep Sogroya® away from direct heat and light.

Meet the pen

Frequently asked questions about using Sogroya®

You may have a few questions about using once-weekly Sogroya®. We’ve got the answers you’re looking for.

Question icon
Can I choose the day of the week that my child takes Sogroya®?

Yes. You pick the day of the week. The chances of sticking to your once-weekly injection schedule increase by keeping to a consistent routine.

How can I prepare for the injection?
  • Set up a consistent routine—routines are an important part of taking Sogroya® as prescribed by your doctor.
  • Choose a comfortable spot with the supplies you’ll need nearby.
  • Give your child their dose when your child is relaxed and mentally prepared. Singing songs, reading a book, or watching a fun video may help.

Be sure to refer to the instructions that came with your Sogroya® pen.

What happens if I miss a dose?

If within 3 days of missed dose: The dose should be taken as soon as possible, and then resume the usual dosing schedule.

If more than 3 days after missed dose: The dose should be skipped, and the next dose should be taken on the regularly scheduled day.

How do I store the Sogroya® pen?

Store the pen with the cap on, in the carton to protect it from light. Store Sogroya® in a refrigerator between uses. Do not store in the freezer or next to the refrigerator cooling element. Sogroya® may be stored temporarily at room temperature (up to 77 ºF) for up to 72 hours. Return Sogroya® to the refrigerator after room temperature storage.e

eThe pen should be refrigerated (36 °F-46 °F). The pen can be taken in and out of a refrigerator as needed. The pen must be discarded 6 weeks after first use, or if it has been frozen, or in temperatures warmer than 86 °F. Keep Sogroya® away from direct heat and light.

For a complete list of frequently asked questions, please visit our FAQ page.

Get started with Sogroya®

Find out about support programs as you start your GH journey.

Get started

Add some creative fun!

Choose from our gallery of free charms and stickers to decorate your Sogroya® pen.

Take a look
Show more Show less

Important Safety Information

Do not use Sogroya® if:

  • you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing problems
  • you have cancer or other tumors
  • you are allergic to somapacitan-beco or any of the ingredients in Sogroya®
  • your healthcare provider tells you that you have certain types of eye problems caused by diabetes
  • you are a child with closed bone growth plates
  • you are a child with Prader-Willi syndrome who is severely obese or has breathing problems including sleep apnea (briefly stopping breathing during sleep)

Before taking Sogroya®, tell your healthcare provider about all of your medical conditions, including if you:

  • have had heart or stomach surgery, trauma, or serious breathing problems
  • have had cancer or any tumor
  • have diabetes
  • have adrenal gland problems
  • are taking replacement therapy with glucocorticoids
  • have thyroid gland problems
  • have liver problems
  • are a child with a history of worsening of curvature of the spine (scoliosis)
  • are pregnant or plan to become pregnant. It is not known if Sogroya® will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant
  • are breastfeeding or plan to breastfeed. It is not known if Sogroya® passes into your breast milk. You and your healthcare provider should decide if you will take Sogroya® while you breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Sogroya® may affect the way some medicines work, and some medicines may affect how Sogroya® works.

How should I use Sogroya®?

  • Use Sogroya® exactly as your healthcare provider tells you to
  • Use Sogroya® 1 time each week
  • If you miss a dose of Sogroya®, the missed dose can be taken within 3 days (72 hours) after the scheduled dosing day. One-time weekly dosing for the next dose can be started again on the regularly scheduled dosing day
  • If more than 3 days (72 hours) have passed, skip the missed dose, and take your next dose on the regularly scheduled dosing day
  • Sogroya® pens are for use by 1 person only
  • Do not share your Sogroya® pens and needles with another person, even if the needle has been changed. You may give another person an infection or get an infection from them

What are the possible side effects of Sogroya®?

Sogroya® may cause serious side effects, including:

  • high risk of death in people who have critical illnesses because of heart or stomach surgery, trauma, or serious breathing problems
  • increased risk of growth of cancer or a tumor that is already present and increased risk of the return of cancer or a tumor in people who were treated with radiation to the brain or head as children and who developed low growth hormone problems. You or your child’s healthcare provider will need to monitor you or your child for a return of cancer or a tumor. Contact the healthcare provider if you or your child start to have sudden changes in behavior, headaches, vision problems, or changes in moles, birthmarks, or the color of your or your child’s skin
  • new or worsening high blood sugar or diabetes. You or your child’s blood sugar may need to be monitored during treatment with Sogroya®
  • increase in pressure in the skull. If you or your child have headaches, eye problems, nausea or vomiting, contact the healthcare provider
  • serious allergic reactions. Get medical help right away if you or your child have the following symptoms: swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, severe itching, skin rashes, redness, or swelling, dizziness or fainting, fast heartbeat or pounding in your chest, sweating
  • your or your child’s body holding too much fluid (fluid retention) such as swelling in the hands and feet, pain in your or your child’s joints or muscles or nerve problems that cause pain, burning or tingling in the hands, arms, legs, and feet. Tell your or your child’s healthcare provider if you or your child have any of these signs or symptoms of fluid retention
  • decrease in a hormone called cortisol. The healthcare provider will do blood tests to check your or your child’s cortisol levels. Tell your or your child’s healthcare provider if you or your child have darkening of the skin, severe fatigue, dizziness, weakness, or weight loss
  • decrease in thyroid hormone levels. Decreased thyroid hormone levels may affect how well Sogroya® works. The healthcare provider will do blood tests to check you or your child’s thyroid hormone levels
  • severe and constant abdominal pain. This could be a sign of pancreatitis. Tell your or your child’s healthcare provider if you or your child has any new abdominal pain
  • loss of fat and tissue weakness in the area of skin you or your child inject. Talk to your or your child’s healthcare provider about rotating the areas where you or your child inject Sogroya®
  • worsening of curvature of the spine in children (scoliosis)
  • hip and knee pain or a limp in children (slipped capital femoral epiphysis)
  • high risk of sudden death in children with Prader-Willi syndrome who are severely obese or have breathing problems, including sleep apnea
  • increase in phosphorus, alkaline phosphatase, and parathyroid hormone levels in your blood. You or your child’s healthcare provider will do blood tests to check this

The most common side effects of Sogroya® in children include: common cold, headache, fever, pain in extremity, and reaction to injection

The most common side effects of Sogroya® in adults include: back pain, joint pain, indigestion, sleep problems, dizziness, swelling of the tonsils (tonsillitis), vomiting, high blood pressure, increase in the level of an enzyme in your blood called creatine phosphokinase, weight gain, and low red blood cells (anemia)

Please click here for Sogroya® Prescribing Information.

Sogroya® is a prescription medication. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

What is Sogroya®?

  • Sogroya® (somapacitan-beco) injection 5 mg, 10 mg or 15 mg is a prescription medicine that contains human growth hormone, the same growth hormone made by the body. 
  • It is given by injection under the skin (subcutaneous) and is used to treat adults and children 2.5 years and older who do not make enough growth hormone.

What is Sogroya®?

  • Sogroya® (somapacitan-beco) injection 5 mg, 10 mg or 15 mg is a prescription medicine that contains human growth hormone, the same growth hormone made by the body. 
  • It is given by injection under the skin (subcutaneous) and is used to treat adults and children 2.5 years and older who do not make enough growth hormone.

Show more Show less
Show more Show less

What is Sogroya®?

  • Sogroya® (somapacitan-beco) injection 5 mg, 10 mg or 15 mg is a prescription medicine that contains human growth hormone, the same growth hormone made by the body. 
  • It is given by injection under the skin (subcutaneous) and is used to treat adults and children 2.5 years and older who do not make enough growth hormone.

What is Sogroya®?

  • Sogroya® (somapacitan-beco) injection 5 mg, 10 mg or 15 mg is a prescription medicine that contains human growth hormone, the same growth hormone made by the body. 
  • It is given by injection under the skin (subcutaneous) and is used to treat adults and children 2.5 years and older who do not make enough growth hormone.

Important Safety Information

Do not use Sogroya® if:

  • you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing problems
  • you have cancer or other tumors
  • you are allergic to somapacitan-beco or any of the ingredients in Sogroya®
  • your healthcare provider tells you that you have certain types of eye problems caused by diabetes
  • you are a child with closed bone growth plates
  • you are a child with Prader-Willi syndrome who is severely obese or has breathing problems including sleep apnea (briefly stopping breathing during sleep)

Before taking Sogroya®, tell your healthcare provider about all of your medical conditions, including if you:

  • have had heart or stomach surgery, trauma, or serious breathing problems
  • have had cancer or any tumor
  • have diabetes
  • have adrenal gland problems
  • are taking replacement therapy with glucocorticoids
  • have thyroid gland problems
  • have liver problems
  • are a child with a history of worsening of curvature of the spine (scoliosis)
  • are pregnant or plan to become pregnant. It is not known if Sogroya® will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant
  • are breastfeeding or plan to breastfeed. It is not known if Sogroya® passes into your breast milk. You and your healthcare provider should decide if you will take Sogroya® while you breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Sogroya® may affect the way some medicines work, and some medicines may affect how Sogroya® works.

How should I use Sogroya®?

  • Use Sogroya® exactly as your healthcare provider tells you to
  • Use Sogroya® 1 time each week
  • If you miss a dose of Sogroya®, the missed dose can be taken within 3 days (72 hours) after the scheduled dosing day. One-time weekly dosing for the next dose can be started again on the regularly scheduled dosing day
  • If more than 3 days (72 hours) have passed, skip the missed dose, and take your next dose on the regularly scheduled dosing day
  • Sogroya® pens are for use by 1 person only
  • Do not share your Sogroya® pens and needles with another person, even if the needle has been changed. You may give another person an infection or get an infection from them

What are the possible side effects of Sogroya®?

Sogroya® may cause serious side effects, including:

  • high risk of death in people who have critical illnesses because of heart or stomach surgery, trauma, or serious breathing problems
  • increased risk of growth of cancer or a tumor that is already present and increased risk of the return of cancer or a tumor in people who were treated with radiation to the brain or head as children and who developed low growth hormone problems. You or your child’s healthcare provider will need to monitor you or your child for a return of cancer or a tumor. Contact the healthcare provider if you or your child start to have sudden changes in behavior, headaches, vision problems, or changes in moles, birthmarks, or the color of your or your child’s skin
  • new or worsening high blood sugar or diabetes. You or your child’s blood sugar may need to be monitored during treatment with Sogroya®
  • increase in pressure in the skull. If you or your child have headaches, eye problems, nausea or vomiting, contact the healthcare provider
  • serious allergic reactions. Get medical help right away if you or your child have the following symptoms: swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, severe itching, skin rashes, redness, or swelling, dizziness or fainting, fast heartbeat or pounding in your chest, sweating
  • your or your child’s body holding too much fluid (fluid retention) such as swelling in the hands and feet, pain in your or your child’s joints or muscles or nerve problems that cause pain, burning or tingling in the hands, arms, legs, and feet. Tell your or your child’s healthcare provider if you or your child have any of these signs or symptoms of fluid retention
  • decrease in a hormone called cortisol. The healthcare provider will do blood tests to check your or your child’s cortisol levels. Tell your or your child’s healthcare provider if you or your child have darkening of the skin, severe fatigue, dizziness, weakness, or weight loss
  • decrease in thyroid hormone levels. Decreased thyroid hormone levels may affect how well Sogroya® works. The healthcare provider will do blood tests to check you or your child’s thyroid hormone levels
  • severe and constant abdominal pain. This could be a sign of pancreatitis. Tell your or your child’s healthcare provider if you or your child has any new abdominal pain
  • loss of fat and tissue weakness in the area of skin you or your child inject. Talk to your or your child’s healthcare provider about rotating the areas where you or your child inject Sogroya®
  • worsening of curvature of the spine in children (scoliosis)
  • hip and knee pain or a limp in children (slipped capital femoral epiphysis)
  • high risk of sudden death in children with Prader-Willi syndrome who are severely obese or have breathing problems, including sleep apnea
  • increase in phosphorus, alkaline phosphatase, and parathyroid hormone levels in your blood. You or your child’s healthcare provider will do blood tests to check this

The most common side effects of Sogroya® in children include: common cold, headache, fever, pain in extremity, and reaction to injection

The most common side effects of Sogroya® in adults include: back pain, joint pain, indigestion, sleep problems, dizziness, swelling of the tonsils (tonsillitis), vomiting, high blood pressure, increase in the level of an enzyme in your blood called creatine phosphokinase, weight gain, and low red blood cells (anemia)

Please click here for Sogroya® Prescribing Information.

Sogroya® is a prescription medication. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Important Safety Information

Do not use Sogroya® if:

  • you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing problems
  • you have cancer or other tumors
  • you are allergic to somapacitan-beco or any of the ingredients in Sogroya®
  • your healthcare provider tells you that you have certain types of eye problems caused by diabetes
  • you are a child with closed bone growth plates
  • you are a child with Prader-Willi syndrome who is severely obese or has breathing problems including sleep apnea (briefly stopping breathing during sleep)

Before taking Sogroya®, tell your healthcare provider about all of your medical conditions, including if you:

  • have had heart or stomach surgery, trauma, or serious breathing problems
  • have had cancer or any tumor
  • have diabetes
  • have adrenal gland problems
  • are taking replacement therapy with glucocorticoids
  • have thyroid gland problems
  • have liver problems
  • are a child with a history of worsening of curvature of the spine (scoliosis)
  • are pregnant or plan to become pregnant. It is not known if Sogroya® will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant
  • are breastfeeding or plan to breastfeed. It is not known if Sogroya® passes into your breast milk. You and your healthcare provider should decide if you will take Sogroya® while you breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Sogroya® may affect the way some medicines work, and some medicines may affect how Sogroya® works.

How should I use Sogroya®?

  • Use Sogroya® exactly as your healthcare provider tells you to
  • Use Sogroya® 1 time each week
  • If you miss a dose of Sogroya®, the missed dose can be taken within 3 days (72 hours) after the scheduled dosing day. One-time weekly dosing for the next dose can be started again on the regularly scheduled dosing day
  • If more than 3 days (72 hours) have passed, skip the missed dose, and take your next dose on the regularly scheduled dosing day
  • Sogroya® pens are for use by 1 person only
  • Do not share your Sogroya® pens and needles with another person, even if the needle has been changed. You may give another person an infection or get an infection from them

What are the possible side effects of Sogroya®?

Sogroya® may cause serious side effects, including:

  • high risk of death in people who have critical illnesses because of heart or stomach surgery, trauma, or serious breathing problems
  • increased risk of growth of cancer or a tumor that is already present and increased risk of the return of cancer or a tumor in people who were treated with radiation to the brain or head as children and who developed low growth hormone problems. You or your child’s healthcare provider will need to monitor you or your child for a return of cancer or a tumor. Contact the healthcare provider if you or your child start to have sudden changes in behavior, headaches, vision problems, or changes in moles, birthmarks, or the color of your or your child’s skin
  • new or worsening high blood sugar or diabetes. You or your child’s blood sugar may need to be monitored during treatment with Sogroya®
  • increase in pressure in the skull. If you or your child have headaches, eye problems, nausea or vomiting, contact the healthcare provider
  • serious allergic reactions. Get medical help right away if you or your child have the following symptoms: swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, severe itching, skin rashes, redness, or swelling, dizziness or fainting, fast heartbeat or pounding in your chest, sweating
  • your or your child’s body holding too much fluid (fluid retention) such as swelling in the hands and feet, pain in your or your child’s joints or muscles or nerve problems that cause pain, burning or tingling in the hands, arms, legs, and feet. Tell your or your child’s healthcare provider if you or your child have any of these signs or symptoms of fluid retention
  • decrease in a hormone called cortisol. The healthcare provider will do blood tests to check your or your child’s cortisol levels. Tell your or your child’s healthcare provider if you or your child have darkening of the skin, severe fatigue, dizziness, weakness, or weight loss
  • decrease in thyroid hormone levels. Decreased thyroid hormone levels may affect how well Sogroya® works. The healthcare provider will do blood tests to check you or your child’s thyroid hormone levels
  • severe and constant abdominal pain. This could be a sign of pancreatitis. Tell your or your child’s healthcare provider if you or your child has any new abdominal pain
  • loss of fat and tissue weakness in the area of skin you or your child inject. Talk to your or your child’s healthcare provider about rotating the areas where you or your child inject Sogroya®
  • worsening of curvature of the spine in children (scoliosis)
  • hip and knee pain or a limp in children (slipped capital femoral epiphysis)
  • high risk of sudden death in children with Prader-Willi syndrome who are severely obese or have breathing problems, including sleep apnea
  • increase in phosphorus, alkaline phosphatase, and parathyroid hormone levels in your blood. You or your child’s healthcare provider will do blood tests to check this

The most common side effects of Sogroya® in children include: common cold, headache, fever, pain in extremity, and reaction to injection

The most common side effects of Sogroya® in adults include: back pain, joint pain, indigestion, sleep problems, dizziness, swelling of the tonsils (tonsillitis), vomiting, high blood pressure, increase in the level of an enzyme in your blood called creatine phosphokinase, weight gain, and low red blood cells (anemia)

Please click here for Sogroya® Prescribing Information.

Sogroya® is a prescription medication. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Important Safety Information

Do not use Sogroya® if:

  • you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing problems
  • you have cancer or other tumors
  • you are allergic to somapacitan-beco or any of the ingredients in Sogroya®
  • your healthcare provider tells you that you have certain types of eye problems caused by diabetes
  • you are a child with closed bone growth plates
  • you are a child with Prader-Willi syndrome who is severely obese or has breathing problems including sleep apnea (briefly stopping breathing during sleep)

Before taking Sogroya®, tell your healthcare provider about all of your medical conditions, including if you:

  • have had heart or stomach surgery, trauma, or serious breathing problems
  • have had cancer or any tumor
  • have diabetes
  • have adrenal gland problems
  • are taking replacement therapy with glucocorticoids
  • have thyroid gland problems
  • have liver problems
  • are a child with a history of worsening of curvature of the spine (scoliosis)
  • are pregnant or plan to become pregnant. It is not known if Sogroya® will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant
  • are breastfeeding or plan to breastfeed. It is not known if Sogroya® passes into your breast milk. You and your healthcare provider should decide if you will take Sogroya® while you breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Sogroya® may affect the way some medicines work, and some medicines may affect how Sogroya® works.

How should I use Sogroya®?

  • Use Sogroya® exactly as your healthcare provider tells you to
  • Use Sogroya® 1 time each week
  • If you miss a dose of Sogroya®, the missed dose can be taken within 3 days (72 hours) after the scheduled dosing day. One-time weekly dosing for the next dose can be started again on the regularly scheduled dosing day
  • If more than 3 days (72 hours) have passed, skip the missed dose, and take your next dose on the regularly scheduled dosing day
  • Sogroya® pens are for use by 1 person only
  • Do not share your Sogroya® pens and needles with another person, even if the needle has been changed. You may give another person an infection or get an infection from them

What are the possible side effects of Sogroya®?

Sogroya® may cause serious side effects, including:

  • high risk of death in people who have critical illnesses because of heart or stomach surgery, trauma, or serious breathing problems
  • increased risk of growth of cancer or a tumor that is already present and increased risk of the return of cancer or a tumor in people who were treated with radiation to the brain or head as children and who developed low growth hormone problems. You or your child’s healthcare provider will need to monitor you or your child for a return of cancer or a tumor. Contact the healthcare provider if you or your child start to have sudden changes in behavior, headaches, vision problems, or changes in moles, birthmarks, or the color of your or your child’s skin
  • new or worsening high blood sugar or diabetes. You or your child’s blood sugar may need to be monitored during treatment with Sogroya®
  • increase in pressure in the skull. If you or your child have headaches, eye problems, nausea or vomiting, contact the healthcare provider
  • serious allergic reactions. Get medical help right away if you or your child have the following symptoms: swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, severe itching, skin rashes, redness, or swelling, dizziness or fainting, fast heartbeat or pounding in your chest, sweating
  • your or your child’s body holding too much fluid (fluid retention) such as swelling in the hands and feet, pain in your or your child’s joints or muscles or nerve problems that cause pain, burning or tingling in the hands, arms, legs, and feet. Tell your or your child’s healthcare provider if you or your child have any of these signs or symptoms of fluid retention
  • decrease in a hormone called cortisol. The healthcare provider will do blood tests to check your or your child’s cortisol levels. Tell your or your child’s healthcare provider if you or your child have darkening of the skin, severe fatigue, dizziness, weakness, or weight loss
  • decrease in thyroid hormone levels. Decreased thyroid hormone levels may affect how well Sogroya® works. The healthcare provider will do blood tests to check you or your child’s thyroid hormone levels
  • severe and constant abdominal pain. This could be a sign of pancreatitis. Tell your or your child’s healthcare provider if you or your child has any new abdominal pain
  • loss of fat and tissue weakness in the area of skin you or your child inject. Talk to your or your child’s healthcare provider about rotating the areas where you or your child inject Sogroya®
  • worsening of curvature of the spine in children (scoliosis)
  • hip and knee pain or a limp in children (slipped capital femoral epiphysis)
  • high risk of sudden death in children with Prader-Willi syndrome who are severely obese or have breathing problems, including sleep apnea
  • increase in phosphorus, alkaline phosphatase, and parathyroid hormone levels in your blood. You or your child’s healthcare provider will do blood tests to check this

The most common side effects of Sogroya® in children include: common cold, headache, fever, pain in extremity, and reaction to injection

The most common side effects of Sogroya® in adults include: back pain, joint pain, indigestion, sleep problems, dizziness, swelling of the tonsils (tonsillitis), vomiting, high blood pressure, increase in the level of an enzyme in your blood called creatine phosphokinase, weight gain, and low red blood cells (anemia)

Please click here for Sogroya® Prescribing Information.

Sogroya® is a prescription medication. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

What is Sogroya®?

  • Sogroya® (somapacitan-beco) injection 5 mg, 10 mg or 15 mg is a prescription medicine that contains human growth hormone, the same growth hormone made by the body. 
  • It is given by injection under the skin (subcutaneous) and is used to treat adults and children 2.5 years and older who do not make enough growth hormone.

What is Sogroya®?

  • Sogroya® (somapacitan-beco) injection 5 mg, 10 mg or 15 mg is a prescription medicine that contains human growth hormone, the same growth hormone made by the body. 
  • It is given by injection under the skin (subcutaneous) and is used to treat adults and children 2.5 years and older who do not make enough growth hormone.

You are about to leave Sogroya.com, a Novo Nordisk website

Click “Continue” to leave the site and come back to visit us another time. Click “Return to site” to stay and learn more about Sogroya® (somapacitan-beco) injection.

Continue

You are about to leave Sogroya.com, a Novo Nordisk website

Click “Continue” to leave the site. Novo Nordisk isn’t responsible for the following content. Come back to visit us another time.

Click “Return to site” to stay and learn more about Sogroya® (somapacitan-beco) injection.

Continue